Alnylam Pharmaceuticals Reiterats 2024 Financial Guidance, Including Combined Net Product Revenues Of $1.4B-$1.5B
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals has reiterated its financial guidance for the full year 2024, projecting combined net product revenues of $1.4B-$1.5B from its products ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. The company expects net product revenue growth of 13% to 21% versus 2023, at both reported FX rates and constant exchange rates (CER). Collaboration and royalty revenues are forecasted to be between $325M-$425M, with GAAP R&D and SG&A expenses projected at $1.9B-$2.05B, and non-GAAP expenses at $1.675B-$1.775B, excluding $225M-$275M in stock-based compensation.
May 02, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals reiterates its 2024 financial guidance, expecting significant revenue growth and controlled expenses, indicating strong performance and operational efficiency.
Reiterating a positive financial guidance, especially with projected revenue growth and a detailed expense forecast, typically instills confidence in investors about the company's future performance and operational efficiency. The specific mention of net product revenues and growth percentages provides a clear financial trajectory, likely leading to a positive short-term impact on ALNY's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100